Skip to content

Study · Randomized controlled trial · n = 18 · 1996

5 results

Lack of effect of recombinant human growth hormone (GH) on muscle morphology and GH-insulin-like growth factor expression in resistance-trained elderly men.

Taaffe DR, Jin IH, Vu TH, Hoffman AR, Marcus R

The Journal of clinical endocrinology and metabolism1 Jan 1996Cited by 72 (Europe PMC)

PMID8550787 (opens in a new tab)DOI10.1210/jcem.81.1.8550787 (opens in a new tab)PepBankPUB-08550787
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In resistance-trained elderly men, rhGH had no group effect on type I muscle fiber area versus placebo.

    In plain wordsIn elderly men doing resistance training, rhGH did not change type I muscle fiber area versus placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeType I muscle fiber area versus placebo
    Study

    n = 18

    Comparator
    Placebo
    Outcome group
    Muscle Morphology · Musculoskeletal
    Studied dose
    0.02 mg/kg BW.day · sc · 10 weeksAs given in this study (human).

    Source sentences

    Summary
    After treatment (weeks 14-24), two-way repeated measures ANOVA revealed a main effect of time for type I (P < 0.01) and type II fibers (P < 0.05), but no group effect or interaction.
    2 context sentences
    Summary · context
    Vastus lateralis muscle samples were obtained by needle biopsy from 18 healthy elderly men (65-82 yr) participating in a double blind, placebo (PL)-controlled trial of recombinant human GH (rhGH) and exercise and assessed for muscle morphology and skeletal muscle tissue expression of GH and insulin-…
    Summary · context
    Subjects initially underwent progressive resistance training for 14 weeks and were then randomized to receive either rhGH (0.02 mg/kg BW.day, sc) or PL while undertaking a further 10 weeks of training.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In resistance-trained elderly men, rhGH had no group effect on type II muscle fiber area versus placebo.

    In plain wordsIn elderly men doing resistance training, rhGH did not change type II muscle fiber area versus placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeType II muscle fiber area versus placebo
    Study

    n = 18

    Comparator
    Placebo
    Outcome group
    Muscle Morphology · Musculoskeletal
    Studied dose
    0.02 mg/kg BW.day · sc · 10 weeksAs given in this study (human).

    Source sentences

    Summary
    After treatment (weeks 14-24), two-way repeated measures ANOVA revealed a main effect of time for type I (P < 0.01) and type II fibers (P < 0.05), but no group effect or interaction.
    2 context sentences
    Summary · context
    Vastus lateralis muscle samples were obtained by needle biopsy from 18 healthy elderly men (65-82 yr) participating in a double blind, placebo (PL)-controlled trial of recombinant human GH (rhGH) and exercise and assessed for muscle morphology and skeletal muscle tissue expression of GH and insulin-…
    Summary · context
    Subjects initially underwent progressive resistance training for 14 weeks and were then randomized to receive either rhGH (0.02 mg/kg BW.day, sc) or PL while undertaking a further 10 weeks of training.
  3. 03HumanNon-randomized trialEfficacy outcome

    In resistance-trained elderly men, type I fiber area changed nonsignificantly by 6.3 +/- 5.9% with rhGH.

    In plain wordsIn elderly men doing resistance training, type I muscle fiber area did not change significantly with rhGH.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeType I muscle fiber area change
    Study

    n: not reported in source

    Outcome group
    Muscle Morphology · Musculoskeletal
    Studied dose
    0.02 mg/kg BW.day · sc · 10 weeksAs given in this study (human).

    Measurements

    Type I fiber area change
    6.3%
    rhGH
    Type I fiber area change, SEM
    5.9%
    rhGH

    Source sentences

    Summary
    For rhGH, the change in type I (6.3 +/- 5.9%) and II (7.1 +/- 5.2%) fiber area was not significant.
    2 context sentences
    Summary · context
    Vastus lateralis muscle samples were obtained by needle biopsy from 18 healthy elderly men (65-82 yr) participating in a double blind, placebo (PL)-controlled trial of recombinant human GH (rhGH) and exercise and assessed for muscle morphology and skeletal muscle tissue expression of GH and insulin-…
    Summary · context
    Subjects initially underwent progressive resistance training for 14 weeks and were then randomized to receive either rhGH (0.02 mg/kg BW.day, sc) or PL while undertaking a further 10 weeks of training.
  4. 04HumanNon-randomized trialEfficacy outcome

    In resistance-trained elderly men, type II fiber area changed nonsignificantly by 7.1 +/- 5.2% with rhGH.

    In plain wordsIn elderly men doing resistance training, type II muscle fiber area did not change significantly with rhGH.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeType II muscle fiber area change
    Study

    n: not reported in source

    Outcome group
    Muscle Morphology · Musculoskeletal
    Studied dose
    0.02 mg/kg BW.day · sc · 10 weeksAs given in this study (human).

    Measurements

    Type II fiber area change
    7.1%
    rhGH
    Type II fiber area change, SEM
    5.2%
    rhGH

    Source sentences

    Summary
    For rhGH, the change in type I (6.3 +/- 5.9%) and II (7.1 +/- 5.2%) fiber area was not significant.
    2 context sentences
    Summary · context
    Vastus lateralis muscle samples were obtained by needle biopsy from 18 healthy elderly men (65-82 yr) participating in a double blind, placebo (PL)-controlled trial of recombinant human GH (rhGH) and exercise and assessed for muscle morphology and skeletal muscle tissue expression of GH and insulin-…
    Summary · context
    Subjects initially underwent progressive resistance training for 14 weeks and were then randomized to receive either rhGH (0.02 mg/kg BW.day, sc) or PL while undertaking a further 10 weeks of training.
  5. 05HumanNon-randomized trialEfficacy outcome

    In resistance-trained elderly men, rhGH produced no apparent change in muscle GH receptor, IGF-I, IGF-I receptor, IGF-II, or IGF-II receptor messenger RNAs.

    In plain wordsIn elderly men doing resistance training, muscle GH receptor and IGF-system messenger RNAs showed no apparent change after rhGH.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeMuscle GH receptor and IGF-system messenger RNAs
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    0.02 mg/kg BW.day · sc · 10 weeksAs given in this study (human).

    Source sentences

    Summary
    No apparent change in tissue GH receptor, IGF-I, IGF-I receptor, IGF-II, or IGF-II receptor messenger ribonucleic acids occurred as a result of exercise after the 14-week pretreatment period or after treatment with rhGH or PL.
    2 context sentences
    Summary · context
    Vastus lateralis muscle samples were obtained by needle biopsy from 18 healthy elderly men (65-82 yr) participating in a double blind, placebo (PL)-controlled trial of recombinant human GH (rhGH) and exercise and assessed for muscle morphology and skeletal muscle tissue expression of GH and insulin-…
    Summary · context
    Subjects initially underwent progressive resistance training for 14 weeks and were then randomized to receive either rhGH (0.02 mg/kg BW.day, sc) or PL while undertaking a further 10 weeks of training.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.